## Variants of Concern

### In the US

<table>
<thead>
<tr>
<th>Variant</th>
<th>Alpha (B.1.1.7)</th>
<th>Beta (B.1.351)</th>
<th>Delta (P.1)</th>
<th>Gamma (B.1.617.2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Identified</td>
<td>United Kingdom</td>
<td>South Africa</td>
<td>Indian</td>
<td>Japan/Brazil</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Spread</th>
<th>May cause people to get very sick &amp; die</th>
<th>Current data do not indicate more severe illness or death than other variants</th>
<th>May cause more severe cases than other variants!</th>
<th>Current data do not indicate more severe illness or death than other variants</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Vaccine Effectiveness</th>
<th>Yes</th>
<th>Yes</th>
<th>Yes</th>
<th>Yes</th>
</tr>
</thead>
</table>

| Treatments | Treatments are effective against this variant | Certain monoclonal antibody treatments are less effective against this variant | Certain monoclonal antibody treatments are less effective against this variant |

### Vacciines and the Variant

Recent studies suggest that the current authorized vaccines are effective against the circulating variants. Scientists will continue to study the effectiveness of the vaccines as variants arise and spread.

**Variants of Interest (VOI)**

*Similar mutations also occur in SARS-CoV-2 variants of interest (VOIs: Epsilon (B.1.427/B.1.429), first detected in the United States-California; Iota (B.1.526), first detected in the United States-New York; Eta (B.1.525), first detected in the United Kingdom/Nigeria; and Kappa (B.1.617.1) and B.1.617.3, first detected in India)(58), but these variants currently have limited prevalence or expansion in the United States or other countries and still lack clear evidence of increased transmission, disease severity, or impact on available vaccines, therapeutics, or diagnostic tests.

### Vacciines and the Variant

Recent studies suggest that the current authorized vaccines are effective against the circulating variants. Scientists will continue to study the effectiveness of the vaccines as variants arise and spread.

**Variants of Interest (VOI)**

*Similar mutations also occur in SARS-CoV-2 variants of interest (VOIs: Epsilon (B.1.427/B.1.429), first detected in the United States-California; Iota (B.1.526), first detected in the United States-New York; Eta (B.1.525), first detected in the United Kingdom/Nigeria; and Kappa (B.1.617.1) and B.1.617.3, first detected in India)(58), but these variants currently have limited prevalence or expansion in the United States or other countries and still lack clear evidence of increased transmission, disease severity, or impact on available vaccines, therapeutics, or diagnostic tests.

### Variants of Concern

- Delta variant is surging in the U.S.
  - Vaccination is more urgent than ever.

### What You Can Do

**Get Vaccinated!**

- Get vaccinated!
- Get vaccinated!
- Get vaccinated!

**In the US**

- Similar mutations also occur in SARS-CoV-2 variants of interest (VOIs: Epsilon (B.1.427/B.1.429), first detected in the United States-California; Iota (B.1.526), first detected in the United States-New York; Eta (B.1.525), first detected in the United Kingdom/Nigeria; and Kappa (B.1.617.1) and B.1.617.3, first detected in India)(58), but these variants currently have limited prevalence or expansion in the United States or other countries and still lack clear evidence of increased transmission, disease severity, or impact on available vaccines, therapeutics, or diagnostic tests.

**Vaccines and the Variant**

Recent studies suggest that the current authorized vaccines are effective against the circulating variants. Scientists will continue to study the effectiveness of the vaccines as variants arise and spread.

**Variants of Interest (VOI)**

*Similar mutations also occur in SARS-CoV-2 variants of interest (VOIs: Epsilon (B.1.427/B.1.429), first detected in the United States-California; Iota (B.1.526), first detected in the United States-New York; Eta (B.1.525), first detected in the United Kingdom/Nigeria; and Kappa (B.1.617.1) and B.1.617.3, first detected in India)(58), but these variants currently have limited prevalence or expansion in the United States or other countries and still lack clear evidence of increased transmission, disease severity, or impact on available vaccines, therapeutics, or diagnostic tests.

**WHAT YOU CAN DO**

**Get Vaccinated!**

- Get vaccinated!
- Get vaccinated!
- Get vaccinated!

**In the US**

- Similar mutations also occur in SARS-CoV-2 variants of interest (VOIs: Epsilon (B.1.427/B.1.429), first detected in the United States-California; Iota (B.1.526), first detected in the United States-New York; Eta (B.1.525), first detected in the United Kingdom/Nigeria; and Kappa (B.1.617.1) and B.1.617.3, first detected in India)(58), but these variants currently have limited prevalence or expansion in the United States or other countries and still lack clear evidence of increased transmission, disease severity, or impact on available vaccines, therapeutics, or diagnostic tests.

**Vaccines and the Variant**

Recent studies suggest that the current authorized vaccines are effective against the circulating variants. Scientists will continue to study the effectiveness of the vaccines as variants arise and spread.

**Variants of Interest (VOI)**

*Similar mutations also occur in SARS-CoV-2 variants of interest (VOIs: Epsilon (B.1.427/B.1.429), first detected in the United States-California; Iota (B.1.526), first detected in the United States-New York; Eta (B.1.525), first detected in the United Kingdom/Nigeria; and Kappa (B.1.617.1) and B.1.617.3, first detected in India)(58), but these variants currently have limited prevalence or expansion in the United States or other countries and still lack clear evidence of increased transmission, disease severity, or impact on available vaccines, therapeutics, or diagnostic tests.

**WHAT YOU CAN DO**

**Get Vaccinated!**

- Get vaccinated!
- Get vaccinated!
- Get vaccinated!